Establishing risk of human experimentation with drugs: lessons from TGN1412

Central Committee on Research Involving Human Subjects, The Hague, Netherlands.
The Lancet (Impact Factor: 39.21). 11/2006; 368(9544):1387-91. DOI: 10.1016/S0140-6736(06)69562-7
Source: PubMed

ABSTRACT Particular care is necessary when a new drug is given to healthy volunteers without previous human testing. General principles for such research have been laid down in guidelines as early as 1983, and these were the basis for many current regulations. 2 Most drugs at that time were small molecules with fairly well characterised, classic, pharmacological mechanisms. Proposed primary objectives for studies in healthy people were therefore to show pharmacological action in man and the dose (or concentration) response curve. This approach was judged safe and was lent support by fi ndings of available surveys. 3,4

1 Bookmark
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die erstmalige Testung des monoklonalen Anti-CD-28-Antikörpers TGN1412 am Menschen zur Behandlung von onkologischen und Autoimmunerkrankungen in London endete in einer Katastrophe mit lebensbedrohlichen Nebenwirkungen für die Probanden, welche durch einen nicht absehbaren Zytokinsturm ausgelöst wurden. Mögliche Fehler und Konsequenzen aus der TGN1412-Katastrophe werden aufgezeigt und in den allgemeinen Kontext der Entwicklung eines Arzneimittels sowie seiner Risiken gesetzt. Risiken der Arzneimitteltestung treten nicht nur bei Hochrisikosubstanzen wie dem TGN1412-Antikörper und in der kritischen Phase der Erstanwendung einer Testsubstanz am Menschen auf, sondern können mitunter erst in späteren Phasen der klinischen Prüfung, insbesondere in den für die Zulassung nötigen Phase-III-Studien, oder gar nach Marktzulassung erkannt werden, wie z. B. im Fall des Cyclooxygenase-2-Inhibitors Rofecoxib (Vioxx®) zur Behandlung von rheumatischen Erkrankungen und akutem Schmerz. Insgesamt haben sich aber die Regularien zur Minimierung von Risiken einer Arzneimitteltestung am Menschen in den letzten Jahrzehnten deutlich entwickelt und werden im Licht von Zwischenfällen wie dem von London mit größter Sorgfalt kontinuierlich modifiziert.
    Der Internist 06/2007; 48(6). · 0.27 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Immunostimulatory antibodies entering the clinic create challenge in terms of not only pharmacodynamics for monitoring anticipated mechanisms but also predetermining cytotoxicity. We show the use of ex vivo whole-blood samples to predict the activation requirements, cytokine signature, and adverse events of an anti-human-CD40 chimeric IgG1 antibody, ChiLob 7/4. Assessments were initially undertaken on human myeloid (mDC1) and plasmacytoid (pDC) dendritic cells, in which an absolute need for cross-linking was shown through the upregulation of activation markers CD83 and CCR7. Subsequent cytokine secretion evaluations of ex vivo whole blood showed the cross-linked antibody-induced increases in MIP1β, interleukin (IL)-8, IL-12, TNFα, and IL-6. This cytokine signature compared favorably with the Toll-like receptor (TLR) ligand lipopolysaccharide (LPS), in which levels of TNFα and IL-6 were significantly higher, suggesting a less intense proinflammatory response and possible modified cytokine release syndrome when used in human trials. Following first-in-human use of this agent within a dose escalation study, in vivo evaluations of dendritic cell activation and secreted cytokines closely matched the predetermined immunomonitoring endpoints. Patients showed a comparable pattern of MIP1β, IL-8, and IL-12 secretion, but no TNFα and IL-6 were identified. Mild symptoms relating to a cytokine release syndrome were seen at an equivalent dosage to that observed for dendritic cell activation and cytokine release. In summary, ChiLob 7/4 induces a distinctive pattern of dendritic cell activation and cytokine secretion in ex vivo assays that can be predictive of in vivo responses. Such preclinical approaches to monoclonal antibody evaluation may inform both the starting dosages and the anticipated cytokine release events that could occur, providing a valuable adjunct for future first-in-human assessments of immunostimulatory antibodies. Cancer Immunol Res; 2(3); 229-40. ©2013 AACR.
    03/2014; 2(3):229-40. DOI:10.1158/2326-6066.CIR-13-0070
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of a new medicine is a risky and costly undertaking that requires careful planning. This planning is largely applied to the operational aspects of the development and less so to the scientific objectives and methodology. The drugs that will be developed in the future will increasingly affect pathophysiological pathways that have been largely unexplored. Such drug prototypes cannot be immediately introduced in large clinical trials. The effects of the drug on normal physiology, pathophysiology, and eventually the desired clinical effects will need to be evaluated in a structured approach, based on the definition of drug development as providing answers to important questions by appropriate clinical studies. This review describes the selection process for biomarkers that are fit-to-purpose for the stage of drug development in which they are used. This structured and practical approach is widely applicable and particularly useful for the early stages of innovative drug development. Expected final online publication date for the Annual Review of Pharmacology and Toxicology Volume 55 is January 06, 2015. Please see for revised estimates.
    Annual Review of Pharmacology 10/2014; 55(1). DOI:10.1146/annurev-pharmtox-011613-135918 · 18.52 Impact Factor

Full-text (2 Sources)

Available from
Dec 14, 2014